Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Placebo-controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On High Doses Of Atorvastatin, Rosuvastatin Or Simvastatin.

NCT01342211 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01342211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01342211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Placebo-controlled, Randomized Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On High Doses Of Atorvastatin, Rosuvastatin Or Simvastatin.
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2011
Completion date
June 30, 2012
Enrollment
93 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemia, hypercholesterolemia